Literature DB >> 12663704

Renal cell carcinoma: a priority malignancy for development and study of novel therapies.

Robert J Motzer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663704     DOI: 10.1200/JCO.2003.12.072

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Epidermal growth factor receptor expression in renal cell carcinoma: rationale for therapy with sidling blockade.

Authors:  Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

2.  High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination.

Authors:  Heike Pohla; Alexander Buchner; Birgit Stadlbauer; Bernhard Frankenberger; Stefan Stevanovic; Steffen Walter; Ronald Frank; Tim Schwachula; Sven Olek; Joachim Kopp; Gerald Willimsky; Christian G Stief; Alfons Hofstetter; Antonio Pezzutto; Thomas Blankenstein; Ralph Oberneder; Dolores J Schendel
Journal:  Mol Med       Date:  2013-02-08       Impact factor: 6.354

3.  Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.

Authors:  Keith Ian Quintyne; Triona Neenan; Liam Casserly; Rajnish Gupta
Journal:  BMJ Case Rep       Date:  2014-05-28

4.  A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.

Authors:  Christiane Geiger; Sybille Regn; Andreas Weinzierl; Elfriede Noessner; Dolores J Schendel
Journal:  J Transl Med       Date:  2005-07-26       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.